Breast Cancer

Pathologic complete response and event-free survival was not found to be significantly affected by race among patients with high-risk breast cancer who received neoadjuvant chemotherapy; however, disparities were observed among patients who did not achieve a pCR.

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Megan Kruse, MD, discusses the results of a study comparing clinical features and outcomes of pleomorphic vs non-pleomorphic invasive lobular carcinoma.

Fulvestrant plus the CDK7 inhibitor samuraciclib demonstrated encouraging efficacy in patients with hormone receptor-positive breast cancer who were heavily pretreated with CDK4/6 inhibitors.

Physicians treating patients with early-stage triple-negative breast cancer should employ circulating tumor DNA testing early and often, according to results from the phase 2 cTRAK TN trial.

Trastuzumab deruxtecan led to prolonged progression-free survival and higher responses vs trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer across all patients subgroups, including those with and without baseline brain metastases.

Peter Schmid, MD, PhD, FRCP, discusses additional results from the phase 3 KEYNOTE-522 trial in early-stage triple-negative breast cancer.

Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Pyrotinib plus capecitabine exhibited longer overall survival (OS), compared with lapatinib plus capecitabine, in patients with HER2-positive breast cancer

Adjuvant treatment with neratinib or ado-trastuzumab emtansine resulted in a greater reduction in the risk of disease recurrence compared with other therapies in an epidemiologic model of HER2-positive, early-stage breast cancer.

Practical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.

Experts take a look at clinical data behind novel antibody drug conjugates and consider how they may impact the management of HER2-low breast cancer.

Focused discussion on the methods used to identify a patient’s HER2 status and why it is important to investigate in patients with breast cancer.

Shared insight on the current state of HER2 classification and testing and in breast cancer, with respect to how it may influence future treatment approaches.

Significant outcome differences were observed in premenopausal vs postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who had 1 to 3 positive lymph nodes and received adjuvant chemotherapy as well as endocrine therapy.

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole resulted in prolonged central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer.

Safety and efficacy data from a pooled pooled analysis confirm that patients who are Black or Hispanic with hormone receptor–positive, HER2-negative breast cancer can be treated with palbociclib plus endocrine therapy.

Carey K. Anders, MD, discusses leveraging antibody-drug conjugates in the treatment of patients with metastatic triple-negative breast cancer.

Black patients with breast cancer were more likely to experience treatment modifications or discontinuations in the neoadjuvant setting compared with White patients.

Kevin Kalinsky, MD, MS, discusses updated results from the phase 3 RxPONDER trial in patients with hormone receptor-positive, HER2-negative breast cancer.

First-line treatment with ribociclib/letrozole improved overall survival over placebo in patients with postmenopausal, hormone receptor–positive, HER2-negative advanced breast cancer, irrespective of metastatic site, number of sites, or prior (neo)adjuvant chemotherapy and endocrine therapy.

Higher Oncotype DX recurrence scores were associated with prolonged persistence to 5 years of endocrine therapy vs lower Oncotype DX recurrence scores in patients with low-risk, estrogen receptor-positive/progesterone receptor–positive breast cancer, according to findings from a retrospective review.

Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.

Datopotamab deruxtecan showed highly encouraging and durable efficacy through overall response rates in patients with advanced or metastatic triple-negative breast cancer.

The combination of entinostat and exemestane led to a significant improvement in progression-free survival compared with placebo and exemestane in Chinese patients with advanced hormone receptor–positive breast cancer.